Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Circulation. 2022 Feb 28;145(9):693–712. doi: 10.1161/CIRCULATIONAHA.121.052792

Figure 2. Clinical Summary Figures of class I guideline recommended medical therapies.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

A) ACEi

B) ARB

C) MRA

D) Beta-Blocker

E) ARNI

F) SGLT2i

Each figure panel provides evidence of the pivotal scientific background of the drug class overall, for different endpoints and stratified for CKD stages. It summarizes the known (and unknown) effect of each drug class on renal function and how to approach a patient with either worsening renal function and/or hyperkalemia.

Abbreviations: ACM: All Cause Mortality, CI: Confidence Interval, CKD: Chronic Kidney Disease, CrCl: Creatinine Clearance, CV: Cardiovascular, eGFR: estimated Glomerular Filtration Rate, HF: Heart Failure, HR: Hazard Ratio, RRR: Relative Risk Reduction, WRF: Worsening Renal Function. For study acronyms see Supplementary Table 1.